Table 1.
Subjects' anthropometric and laboratory characteristics at baseline and after 26 weeks of treatment.
| Pioglitazone | Insulin glargine |
Δ pioglitazone vs. Δ insulin glargine P |
|||||
| Week 0 | Week 26 | P | Week 0 | Week 26 | P | ||
| 15 | 15 | ||||||
| Men/women | 11/4 | 9/6 | |||||
| Age(years) | 60.8 ± 7.1 | 61.5 ± 8.2 | |||||
| Diabetes Duration (years) | 11.1 ± 6 | 9.5 ± 7.5 | |||||
| BMI (kg/m2) | 30.8 ± 5.5 | 31.9 ± 5.9 | 0.001 | 31.6 ± 6.1 | 32.5 ± 6.2 | 0.01 | 0.37 |
| HbA1c (%) | 8.1 ± 1.5 | 6.8 ± 1.2 | 0.001 | 8.3 ± 1.4 | 6.1 ± 0.7 | 0.001 | 0.23 |
| Haemoglobin (g/l) | 137.5 ± 11.4 | 127 ± 12.0 | 0.001 | 137.1 ± 10.2 | 132 ± 12.0 | 0.02 | 0.13 |
| Cholesterol (mmol/l) | 4.4 ± 0.9 | 4.2 ± 0.7 | 0.17 | 4.3 ± 1.0 | 4.1 ± 1.0 | 0.32 | 0.65 |
| HDL (mmol/l) | 1.1 ± 0.2 | 1.3 ± 0.3 | 0.01 | 1.1 ± 0.4 | 1.1 ± 0.4 | 0.49 | 0.01 |
| LDL (mmol/l) | 2.4 ± 0.9 | 2.3 ± 0.5 | 0.64 | 2.3 ± 0.7 | 2.4 ± 0.7 | 0.46 | 0.48 |
| TG (mmol/l) | 1.8 ± 0.8 | 1.5 ± 1.0 | 0.002 | 1.9 ± 1.3 | 1.5 ± 1.0 | 0.009 | 0.43 |
| ALT (μcat/l) | 0.7 ± 0.7 | 0.4 ± 0.3 | 0.04 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.12 | 0.87 |
| Systolic blood pressure | 142 ± 16 | 134 ± 10 | 0.04 | 146 ± 17 | 132 ± 13 | 0.02 | 0.39 |
| Diastolic blood pressure | 84 ± 8 | 77 ± 7 | 0.02 | 81 ± 8 | 73 ± 8 | 0.007 | 0.57 |
| BNP (pmol/l) | 6.9 ± 5.2 | 14.1 ± 16.7 | 0.10 | 9.7 ± 12.9 | 9.7 ± 11.6 | 0.41 | 0.51 |
| NT-proBNP (ng/l) | 11.4 ± 19.6 | 22.8 ± 44.0 | 0.046 | 13.6 ± 20.0 | 10.1 ± 9.5 | 0.97 | 0.23 |
Values are mean ± SD. There were no significant differences between subjects' characteristics at start or after 26 weeks of treatment.